China chip stocks rally on self-reliance bets, Nvidia scrutiny
Investing.com - Cantor Fitzgerald has maintained its Overweight rating and $3.00 price target on Lucid (NASDAQ:LCID) Diagnostics Inc (NASDAQ:LUCD) following the company’s second-quarter 2025 financial results. With a market capitalization of approximately $104 million and analyst targets ranging from $2 to $7.75, InvestingPro data shows the stock trading near its Fair Value.
Lucid Diagnostics reported revenue of $1.2 million for the second quarter, representing year-over-year growth of approximately 19%, driven by increased volume of its EsoGuard diagnostic test. The reported revenue exceeded FactSet consensus estimates of $1.1 million but fell short of Cantor Fitzgerald’s projection of $1.5 million. InvestingPro analysis reveals concerning metrics, including a -59% gross profit margin and significant cash burn. Pro subscribers have access to 6 additional key insights about LUCD’s financial health.
The company performed 2,756 tests during the quarter, which falls within its target range of 2,500-3,000 tests per quarter. This testing volume reflects the company’s continued focus on expanding the adoption of its EsoGuard diagnostic platform.
MolDx will convene a Contractor Advisory Committee on September 4, 2025, to evaluate clinical evidence related to EsoGuard as part of the reconsideration process for LCD L39256. This meeting represents a significant milestone in Lucid’s efforts to secure Medicare coverage for its diagnostic test.
Lucid Diagnostics believes it is approaching a local coverage decision that would secure Medicare coverage for EsoGuard, which could potentially shift the company’s narrative from volume growth to revenue generation as reimbursement improves.
In other recent news, Lucid Diagnostics Inc. announced its second-quarter 2025 earnings, which showed a slight beat on earnings per share (EPS) expectations. The company reported an EPS of -$0.10, surpassing the anticipated -$0.11. Revenue for the quarter was in line with projections at $1.16 million. Despite exceeding EPS forecasts, the revenue figures did not present any unexpected changes. These developments have been noted by analysts and investors alike. The earnings report is part of the company’s ongoing financial disclosures. Lucid Diagnostics continues to attract attention with its financial results, as stakeholders assess the implications of these figures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.